

OPTIMISING OUTCOMES OF PATIENTS WITH ADVANCED PROSTATE AND UROTHELIAL CANCER

Chairs

Ravindran Kanesvaran,
Singapore

Karim Fizazi,
Villejuif, France

SATURDAY, 21 NOVEMBER 2020

17:35-19:05 SGT, CHANNEL 3

17:35	Live introduction	Karim Fizazi, Villejuif, France
17:40	Optimal combinations of systemic therapies in treatment-naive patients with advanced hormone-sensitive prostate cancer: Which ones and for which patients?	Arnulf Stenzl, Tuebingen, Germany
17:55	How do modern first-line combination regimens affect the therapeutic algorithm in later lines of therapy in metastatic prostate cancer?	Karim Fizazi, Villejuif, France
18:10	State of the art therapeutic landscape in non-metastatic castration-resistant prostate cancer	Philip Kwong, Hong Kong, China
18:25	Emerging systemic therapies in unresectable bladder cancer: Immunotherapy, kinase inhibitors and antibody-drug conjugates	Matthew Galsky, New York, NY, USA
18:40	Key messages and wrap up	Ravindran Kanesvaran, Singapore
18:50	Live Q&A	

This educational activity is provided by ESMO and supported by Astellas Pharma Singapore Pte. Ltd.